AMNOG - How will Germany's Healthcare Reform Impact Global Pricing and Reimbursement Strategies?
The restructuring of the German pricing and reimbursement system - AMNOG - is bringing significant challenges for pharmaceutical industry players operating in the country. This major German healthcare reform is likely to favour innovative drug makers, and place more emphasis on evidence-based medicine.
In our new study Optimising Market Access Strategies Under AMNOG: How will Germany's Healthcare Reform Impact Global Pricing and Reimbursement Strategies, we examine the German healthcare reform and what it means for the pharmaceutical industry. The study will include:
- Analysis of the drivers behind AMNOG
- Details of new pricing and reimbursement rules
- Analysis of the design requirements of new clinical trials
Watch Our Complimentary On-Demand Webcast:
The Impact of AMNOG on Global Pharmaceutical Market Access Strategies
In this webcast we examine the German healthcare reform and what it means for the global pharmaceutical industry. We discuss the key findings of our study, including:
- The impact of AMNOG on national and global market access strategies for medicines subject to early benefit assessment
- How the reform may impact your clinical trial development
- How innovative the reform is from an international perspective
Featured Speakers:
Gustav Ando, Director, Global Healthcare Products, IHS Global Insight
Gaelle Marinoni, Senior Healthcare Analyst, IHS Global Insight
Anne-Charlotte Honore, Healthcare Analyst, IHS Global Insight
Watch this complimentary on-demand webcast
Contact Us
+44 (0) 203 159 3386
Downloads
Study Table of Contents
I. Executive Summary
II. Methodology
III. Rationale Behind Germany's P&R Reform
IV. Details of the new P&R environment in Germany
V. Reimbursement Dossier Requirements Under New Reform
VI. Impact of AMNOG on Market Access Strategies in a Global Context
a. Impact on German Market Access Strategies, clinical trial design, pricing and contracting strategies
b. Impact on Global Market Access Strategies and Launch Sequence
United States














